Contagion Live news story
Aicuris announced positive results from its phase 3 PRIOH-1 trial evaluating its investigational antiviral, pritelivir, in immunocompromised patients (including people living with HIV) with refractory herpes simplex virus (HSV) infections, with or without antiviral resistance. The findings represent a major advance for a patient population with few effective and well-tolerated treatment options.
The global, controlled, open-label study assessed the efficacy and safety of pritelivir, a first-in-class helicase-primase inhibitor, compared with investigator’s choice therapy (ICT). Current ICT options for refractory HSV — such as intravenous foscarnet, cidofovir, or topical imiquimod — are often limited by toxicity, resistance, and the need for prolonged intravenous administration in healthcare settings.
Read the full news story here.
Source : Contagion Live
Related HIV and Co-Infections News
-
TheBodyPro: A new study on HIV, hypertension, and pregnancy is about a lot more than it seems
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
ACTG launches landmark study evaluating treatments for depressive disorders with or without mild neurocognitive disorder among people living with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.